Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients

Inclusion Criteria: * Age: 25-75 years old. * Gender: female * Newly diagnosed HER2 positive breast cancer patients who are scheduled to receive doxorubicin followed by trastuzumab adjuvant therapy. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2 * Preserved LV systolic function in which the left ventricular ejection fraction (LVEF)≥50%. * Patients with normal renal and hematological functions. * Alanine amino transferase (ALT ≤ 3 times ULN). Exclusion Criteria: * Pregnant or lactating females. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) \> 2 * Patients with impaired LV systolic function in which the left ventricular ejection fraction (LVEF)\<50%. * Patients with significant valvular heart disease, documented coronary artery disease, history of congestive heart failure or cardiomyopathy. * Alanine amino transferase (ALT \> 3 times ULN). * Patients already taking statins or other lipid lowering therapy. * Patients with a known hypersensitivity to any of the used drugs.